Venture Accelerator

  • Caribou Ventures was founded with one simple premise. It is our belief that all entrepreneurs, from all backgrounds, benefit from having an institutional investor guidance to help them scale and grow their company from the very beginning. We have built the entire firm around this premise that helping entrepreneurs get started and scale will be our life’s work. To that end, we have six core principles that drive our decisions and strategy:
  • We are unafraid to back unproven, first-time entrepreneurs; unproven is not the same as incapable. We believe that the greatest returns in venture come from entrepreneurs who are capable but have not yet had the opportunity to show the world their talents and capabilities. We aggressively back entrepreneurs who have something to prove.
  • We invest in pre-seed, seed and series A companies  creating innovation through technology across industriies.  We are hands on through the lifecycle, build networks, brand exposure, attract talent, raise follow on rounds and find a path to acquisition, SPAC or IPO.
  • We hold ourselves to high standards in terms of the diversity of founders we back and support. We are committed to investing in founders who represent a wide variety of backgrounds in terms of gender, race, background, academic experience and life circumstances.
  • We are patient because building meaningful companies takes time and the rewards are great for those who participate in the entire journey. Building great 
  • We want to invest in your first institutional round of investment. We do not have requirements for traction or metrics. We want to be part of the company as early as possible. 
  • We are actively involved with our early stage companies by developing to enable them to source financing, build a team of influential advisors and position the Founders to grow and succeed in achieving their goals.
  • Our skill-sets and backgrounds as leading professionals across sectors will enable your firm to not only raise capital but also build a network, successfully manage competition in the market and access the technical, legal, and regulatory guidance needed to thrive.

A product or service in beta (versus alpha) stage of development and has been created with input from clients or potential clients

  • “Proof of concept” revenue or significant pilots, except for health care bio/pharma, diagnostics and devices companies
  • A plausible exit strategy within 5-8 years
  • Typical valuation at first funding below $5 million
  • Typically seeking first-round of funding of $250,000-$2,000,000
  • For consumer product companies, additional criteria include:
  • Annual run rate revenue over $1,000,000
  • Gross margins over 40%
  • For health care companies, (bio/pharma, diagnostics and devices), additional investment considerations include
  • Consumer – revenue pending orders
  • Heathcare- Protectable intellectual property with protection in process or granted
  • Products or services that fill a significant unment need
  • A concept based on verifiable science that validates approach and supports expectation of efficacy
  • Articulated pathways, with projected timing, for regulatory and reimbursement approvals (if applicable)
  • Company understanding of the studies required to drive adoption (blind clinical studies, for example), their design and cost
  • Clinical partnerships or connections that will allow access to patients for clinical trials and to help drive adoption
  • Defined approach for product manufacturing and scaling, or rationale for why this is not necessary
  • Understanding of capital requirements, future funding strategies and expected milestones needed to effect such strategies
  • For device companies, meaningful and positive in vitro, and ideally in vivo data that has been validated externally or with validation underway
  • For diagnostic companies, strong retrospective, and ideally prospective, data that has been validated externally or with validation underway
  • A concept based on verifiable science that validates approach and supports expectation of efficacy
  • Articulated pathways, with projected timing, for regulatory and reimbursement approvals (if applicable)
  • Company understanding of the studies required to drive adoption (blind clinical studies, for example), their design and cost
  • Clinical partnerships or connections that will allow access to patients for clinical trials and to help drive adoption
  • Defined approach for product manufacturing and scaling, or rationale for why this is not necessary
  • Understanding of capital requirements, future funding strategies and expected milestones needed to effect such strategies
  • For device companies, meaningful and positive in vitro, and ideally in vivo data that has been validated externally or with validation underway
  • For diagnostic companies, strong retrospective, and ideally prospective, data that has been validated externally or with validation underway
  • In addition to leading institutional seed rounds, NextView also offers a virtual accelerator program for the earliest stage companies in need of smaller dollars and hands-on mentorship. This accelerator differs from our typical investing in that there is a standardized deal, engagement model, and follow-on financing policy.
  • We have created this program because we recognize that VC investment tends to flow towards founders with established VC relationships rather than a more diverse set of equally capable founders.  Additionally, many historical accelerators have shifted from being true pre-seed catalysts to programs overly focused on existing traction to optimize follow-on funding hit rates. This is a hyper-focused program with high engagement from the NextView partners and our close knit industry leading advisors. For more details on this accelerator, see the information below or our original blog post launching the program.
  • Members – we have x number of angel investors and over 40000 accreditted investors who are involved in the investment process, signature pitch process,
  •  We provide capital to invest in early start companies who have a technology adjacent focus across industry sectors.  Our firm is comprised of seasoned investors, operators, C suite executives, entrepreneurs, finance and business development executives who are committed to supporting companies who aim to achieve innovative breakthroughs and financial success while practicing conscious capitalism. 
  • We are actively involved with our portfolio companies to enable them to source financing, build a team of influential advisors and position the Founders to grow and succeed in achieving their goals.
  • Our skill-sets and backgrounds as leading professionals across sectors will enable your firm to not only raise capital but also build a network, successfully manage competition in the market and access the technical, legal, and regulatory guidance needed to thrive.



  • We focus on early-stage companies ranging from pre-seed to Series A. All companies will be able to leverage our firm’s extensive sector expertise and work with our team who have successfully founded, invested in and exited businesses.  
  • Hosting paractive and full investor pitch
  • Our focus is on tech adjacent firms across sectors including, financial services, software, e-commerce healthcare, cleantech, fin tech, defence, B2B, B2C, AI, enterprise SaaS, big data, cyber, and machine learning.
  • We deliver real value through our extensive global network of investors and venture partners. We have a team of seasoned entrepreneurs and industry leaders keen to help guide you to the next level.
  • We fully manage the capital raising process for you which is comprised of dedicated discretionary capital along side a wider global network of co-investors who are keen to invest in add on and later stage capital raising. Our investors in include HNW, family offices, tech entrepreneurs, and intuitional and government foundations.
  • Our investment committee is comprised of our leadership team who will serve as your support team.  Our team has successfully invested on over xx companies who have gone on to raise additional capital and grow into large successful companies. Our team recognizes that we are at the precipice of both great innovation while also facing imminent challenges to the global community. With the pandemic demanding solutions to keep people connected and productive it has also highlighted how archaic most companies operate.  There is an unprecedented opportunity to create solutions for people and the companies which comprise our economy.